RAF265 (CHIR-265)
Catalog No. A10773
RAF265 (CHIR-265)是一种口服,高度选择性的RAF和VEGFR激酶抑制剂,可控制或正常化VEGFR-2,同时抑制B-raf和c-Raf突变以预防癌症。
Catalog Num | A10773 |
---|---|
M. Wt | 518.4 |
Formula | C24H16F6N6O |
Purity | >98% |
Storage | at -20°C 3 years Powder |
CAS No. | 927880-90-8 |
Synonyms | |
SMILES | CN1C2=C(C=C(C=C2)OC3=CC(=NC=C3)C4=NC=C(N4)C(F)(F)F)N=C1NC5=CC=C(C=C5)C(F)(F)F |
RAF265 (CHIR-265)是一种口服,高度选择性的RAF和VEGFR激酶抑制剂,可控制或正常化VEGFR-2,同时抑制B-raf和c-Raf突变以预防癌症。
Targets
VEGFR2 (Cell-free assay) | B-Raf (Cell-free assay) | |||
30 nM(EC50) | 3 nM-60 nM |
In vitro (25°C) | DMSO | 85 mg/mL (163.96 mM) | |
Water | Insoluble | ||
Ethanol | 28 mg/mL (54.01 mM) | ||
In vivo | 30% PEG400+0.5% Tween80+5% propylene glycol | 28 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 19.29 mL | 96.45 mL | 192.9 mL |
0.5 mM | 3.86 mL | 19.29 mL | 38.58 mL |
1 mM | 1.93 mL | 9.65 mL | 19.29 mL |
5 mM | 0.39 mL | 1.93 mL | 3.86 mL |
*The above data is based on the productmolecular weight 518.4 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.